Clindamycin shows promise as alternative treatment to antibiotics in hidradenitis suppurativa
A recent study has demonstrated the potential of clindamycin as a treatment alternative to antibiotic combination regardless of hidradenitis suppurativa (HS) clinical stage.
This study classified a total of 60 patients with mild-to-moderate-severe HS according to their International Hidradenitis Suppurativa Severity Score System (IHS4) and Hurley scores. Patients were then subdivided into two groups of 30 members each (group A patients received clindamycin plus rifampicin; group B patients were treated with clindamycin alone) and analysed retrospectively.
The authors examined and compared the clinical and ultrasound responses between the groups after 8 weeks of treatment according to the Hidradenitis Suppurativa Clinical Response measure.
Seventeen patients in group A and 19 patients in group B showed clinical responses after the treatment. Improvement in IHS4 score was comparable between the two groups, but group B patients showed better improvement in the Dermatology Life Quality Index and pain Visual Analogue Scale scores.
Furthermore, the two groups had similar reductions in nodule and abscess counts, but patients in group B had greater decrease in the number of draining tunnels.
Age, body mass index, IHS4 score and absence of axillary involvement were significantly associated with Hidradenitis Suppurativa Clinical Response score. Disease-free survival was also comparable between groups A and B.
One limitation of the study was that it was not randomized or placebo-controlled, the authors said.
“Antibiotics are recognized as first-line treatments for HS, but the data on their efficacy are limited,” they noted.